Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →
logo
Get CLEATUSFree Trial

Vaccine Antigen and Adjuvant Manufacturing

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract pertains to the manufacture of bulk influenza vaccine antigens and adjuvanted formulations in compliance with current good manufacturing practices for use in clinical trials and emergency response scenarios. The work must adhere to stringent quality and regulatory standards to ensure safety and efficacy, with production intended to support public health preparedness and rapid deployment during outbreaks. The place of performance is designated as Washington, DC, with a delivery deadline for responses set for August 15, 2026. This subcontract falls under the NAICS code 325412, indicating classification within pharmaceutical and medicine manufacturing, and is issued by the Biomedical Advanced Research and Development Authority under the Department of Health and Human Services. Participation requires capability to scale production while maintaining cGMP compliance across all stages of antigen and adjuvant formulation, with no set-aside provisions specified for small or disadvantaged businesses.

General Info

Manufacture of influenza vaccine antigens and adjuvanted formulations under cGMP for clinical trials and emergency use in Washington, DC by August 15, 2026.

Agency

Department Of Health And Human Services → Barda - Aspr / Daappo / Barda DcmaView Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

Washington, DC, 20024, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Manufacture bulk influenza vaccine antigens and adjuvanted formulations under cGMP for clinical and emergency use.

Similar Contracts

Same NAICS industry code

NAICS: 325412
New
DIBBS
BUPIVACAINE AND EPINEP
Solicitation # SPE2DP-26-T-4389
The contract specifies the procurement of bupivacaine and epinephrine injection in 1.8 mL cartridges containing 0.500% w/v bupivacaine hydrochloride and 0.005 mg epinephrine per mL (1:200,000), supplied in lots of 50 cartridges per container, with a total quantity of two containers. The product must be stored at controlled room temperature between 15 and 30 degrees Celsius and maintain a minimum shelf life of 15 months at the time of delivery to the first government activity, despite an 18-month maximum shelf life. All packaging must comply with Medical Marking Standard No. 1, superseding MIL-STD-129, and must be commercially packaged to ensure protection from damage and safe transport via common carrier at lowest cost to the destination. The material is not considered hazardous under FED-STD-313 and must be packaged in accordance with ASTM D3951, though all DLA Technical and Quality Requirements take precedence. Mercury or mercury-containing compounds are prohibited in direct contact with the product, except for functional uses in batteries, instruments, or sensors as permitted under NAVSEA guidelines. Delivery is required FOB destination within 20 days of order placement to the USS MIGUEL KEITH (ESB-5) in San Diego, California, with no tolerance for quantity variance. The item is identified by NSN 6505-01-189-3973 and referenced under Purchase Request 7017681406, with multiple approved manufacturers listed including DENTAL HEALTH PRODUCTS INCORPORATED, CARESTREAM DENTAL LLC, PATTERSON DENTAL, HENRY SCHEIN, INC., and BENCO DENTAL SUPPLY CO. All packaging and labeling must adhere to DLA Packaging Requirements for Procurement and palletization standards, and shipment details include vessel-specific transport instructions and government-only tracking identifiers.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
CARPROFEN TABLETS
Solicitation # SPE2DP-26-T-4392
Carprofen Tablets 100mg are chewable nonsteroidal anti-inflammatory, analgesic, and antipyretic tablets specifically formulated for dogs, supplied in bottles of 60 tablets each. The product is regulated by the FDA and must comply with the DLA Master List of Technical and Quality Requirements, including packaging standards per Medical Marking Standard No. 1 and MIL-STD-2073-1E, with no tolerance for quantity variance. It is classified as a Type I (Code Q) item with a fixed 36-month shelf life that is non-extendable and must be stored at controlled room temperature between 15–30°C (59–86°F). The item is procured under solicitation SPE2DP-26-T-4392 with a delivery requirement of 20 days FOB destination, and inspection and acceptance occur at the delivery point. Only approved manufacturers including Zoetis Inc., Covetrus North America, LLC, and Patterson Veterinary Supply, Inc. with specified part numbers are eligible, and all supplies must be properly marked in accordance with government standards. The contracting official must submit a referral through EBS to confirm product suitability before award, and the item is identified by NSN 6509014874464 under the Department of Defense’s Medical Supply Chain PHARM FSA.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
PENTOBARBITAL SODIU
Solicitation # SPE2DP-26-T-4387
Pentobarbital Sodium Injection, Veterinary, is a Schedule II controlled substance with high abuse potential, supplied in 250ml vials containing 6 grains of sodium pentobarbital for euthanasia purposes. Each unit is classified as a Type I (Code M) item with a non-extendable shelf life of 24 months and must be stored under vault conditions at room temperature in compliance with DEA regulations for Schedule II drugs. The product is regulated by the FDA and must be labeled and accompanied by Safety Data Sheets (SDS) aligned with OSHA’s Hazard Communication Standard and the Globally Harmonized System, effective after June 1, 2015. Labeling and documentation must conform to 29 C.F.R. 1910.1200, and suppliers are required to train employees on these requirements. All packaging must adhere to MIL-STD-2073-1E and the latest Medical Marking Standard No. 1, with government identification removed from non-accepted supplies per RQ011. The contract, issued under solicitation SPE2DP-26-T-4387, specifies a quantity of two units, each costing $2.00, for a total price of $4.00, with delivery required within five days FOB destination. Inspection and acceptance occur at the delivery point, with zero tolerance for quantity variance. The NSN is 6509-01-485-6206, and the item is procured under the DOD’s authorized unit of issue. The point of contact for the procurement is Shairy M. Cartagena of the Department of Defense’s Medical Supply Chain PHARM FSA, with performance taking place at Lackland AFB. The product is supplied by Patterson Veterinary Supply, Inc. and Covetrus North America, LLC, identified by respective part numbers, and the acquisition falls under NAICS code 325412.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
LIDOCAINE HYDROCHLORID
Solicitation # SPE2DP-26-T-4390
Lidocaine Hydrochloride and Epinephrine Injection, USP, in a 2% concentration with a 1:100,000 epinephrine ratio, is supplied in 1.7 mL cartridges packaged in units of 50 per PG, with a total shelf life of 15 months. A minimum of 13 months of remaining shelf life is required at the time of receipt by the first government activity, and the product must be stored at controlled room temperature below 25°C (77°F), protected from light and prevented from freezing. It is labeled as latex-free and intended exclusively for local dental anesthesia via nerve block or infiltration. Packaging must conform to Commercial standards as specified in DLA’s packaging requirements, with all units sealed in protective containers and shipped in exterior containers suitable for safe delivery by common carrier at the lowest cost. Labeling and marking must comply with Medical Marking Standard No. 1, superseding MIL-STD-129, and all packaging must adhere to the DLA Master List of Technical and Quality Requirements, which take precedence over ASTM D3951. Hazardous material shipping requirements specified in FED-STD-313 and TQ requirement IP025 apply if applicable, and palletization must follow RP001 guidelines. The product is regulated by the FDA and requires pre-award confirmation through EBS referral. The contract specifies three line items under solicitation SPE2DP-26-T-4390, all referencing the same NSN: 6505-01-597-1328, with delivery due within five days of award and FOB destination. Quantity requirements total 12 PGs (1200 cartridges), distributed across three delivery points: USS Tulsa (LCS-16), USS Princeton (CG-59), and the Carrier Outfitting Material Support Center in Suffolk, VA. Shipment must be sent by the fastest traceable means, prohibiting parcel post, and each order must include the correct unit of issue and quantity per unit pack. The solicitation was posted July 30, 2026, with responses due by August 5, 2026, and required delivery dates range between August 3 and August 4, 2026. Vendors are identified as Darby Dental Supply, Henry Schein Inc., and Benco Dental Supply Co., with specific part and N
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
WATER FOR INJECTION, ST
Solicitation # SPE2DP-26-T-4380
Water for Injection, Sterile, USP, is supplied in 1000ml plastic bags, packaged in units of 12 bags per package, with a total procurement quantity of 2 packages. The item is regulated by the FDA and requires strict adherence to medical marking standards, specifically the latest edition of Medical Marking Standard No. 1, as defined by DLA. It must be stored at controlled room temperature and carries a non-extendable shelf life of 24 months, classified as a TYPE I (CODE M) item under DLA requirements. All packaging and labeling must comply with MIL-STD-2073-1E and the DLA Packaging Requirements for Procurement, with government identification removed from non-accepted supplies. The product is sourced from approved manufacturers including B. BRAUN MEDICAL INC and ICU MEDICAL, INC, each with designated NDC numbers. Delivery is required FOB destination within five days of contract award, with zero variance allowed in quantity. Inspection and acceptance occur at the delivery point, with the NSN 6505-01-386-9046 and procurement reference PR 7017669520. The solicitation, issued under SPE2DP-26-T-4380, was posted on July 30, 2026, with responses due by August 5, 2026, and is managed by the Department of Defense's Medical Supply Chain Pharm FSA, with primary point of contact James Foggie.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
ERYTHROMYCIN OPHTHALMI
Solicitation # SPE2DP-26-T-4394
ERYTHROMYCIN OPHTHALMIC OINTMENT USP is a sterile, topical ointment containing 5 mg of erythromycin per gram in a base of mineral oil and white petrolatum, intended for ophthalmic use only. Each unit is packaged as a single-dose tube containing 3.5 grams of ointment, with 24 tubes per package, defined as the unit of issue. The product must have a minimum of 31 months of remaining shelf life upon receipt by the first government activity, as its total shelf life is 36 months and is non-extendable. Storage requirements mandate controlled room temperature between 15°C and 30°C (59°F–86°F), with protection from excessive heat and freezing. All packaging and labeling must strictly adhere to Medical Marking Standard No. 1A dated February 4, 2013, superseding MIL-STD-129, and must comply with DLA’s Master List of Technical and Quality Requirements. The ointment is regulated by the FDA and must be marked and shipped in accordance with commercial packaging standards, specifically ASTM D3951 if not classified as hazardous under FED-STD-313; however, DLA requirements take precedence over all other standards. Each shipment must be delivered FOB destination within five days, using the fastest traceable means, excluding parcel post, to the specified delivery point at Fort Lewis, WA. The product is identified by NSN 6505-01-189-7090, with a single purchase order quantity of one package, and the manufacturer is PADAGIS US LLC under NDC 00574-4024-39.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
RINGER'S INJECTION, LAC
Solicitation # SPE2DP-26-T-4395
RINGER'S INJECTION, LACTATED, USP, 1000ML, in packs of 12 units per case, is being procured under contract SPE2DP-26-T-4395 with a total order of 7 packing groups, equivalent to 84 individual units. The product is manufactured by B. Braun Medical Inc. with NDC 00264-7750-00 and is subject to FDA regulation. Packaging must comply strictly with Medical Marking Standard No. 1, superseding all references to MIL-STD-129, and must ensure protection from damage and breakage during transit. Each unit must be sealed and packed in commercial shipping containers suitable for safe delivery via common carrier at the lowest cost to the specified destination, which is FPO AP 96675. The item has a non-extendable shelf life of 30 months and must be stored at room temperature (25°C), with brief exposure up to 40°C permitted. Packaging must adhere to DLA’s RP001 requirements and the latest DLA Master List of Technical and Quality Requirements, which take precedence over ASTM D3951. No hazard classification applies under FED-STD-313, so commercial packaging per ASTM D3951 is acceptable but subordinate to DLA standards. Delivery is required within 20 days of contract award, with zero quantity variance allowed, and inspection and acceptance occur at the delivery point. The unit of issue is packing group (PG), with each PG containing 12 units. All markings, labeling, and palletization must conform to specified DLA and federal standards, and shipping instructions must follow DLAD Proc Note C19 and C20. The solicitation closed on August 5, 2026, with an original required delivery date of August 3, 2026.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
POVIDONE-IODINE CLEANS
Solicitation # SPE2DP-26-T-4384
POVIDONE-IODINE CLEANSING SOLUTION, USP, with 7.5% active ingredient, is procured for external use only in 1-gallon bottles, designated by the unit of issue BT, with a total shelf life of 36 months; at least 31 months of shelf life must remain upon delivery to the first government activity. Storage must be maintained at 25°C (77°F), with permitted excursions between 15°C and 30°C (59°F to 86°F). The product is regulated by the FDA and must comply with all applicable DLA Master List of Technical and Quality Requirements, including packaging standards RP001 and labeling mandates under the Hazard Communication Standard, requiring Safety Data Sheets and GHS-compliant labels submitted for approval prior to award. All packaging must adhere to Medical Marking Standard No. 1, superseding MIL-STD-129, and be commercially sealed to prevent damage, with palletization following DLA guidelines. The item is classified as hazardous per Fed-Std-313 and must be packaged according to TQ requirement IP025. Five 1-gallon units are required under two contract line items, both with identical NSN 6505009947224, each priced individually, with zero variance allowed in quantity. Delivery is FOB destination within 20 days, inspected and accepted at the destination point. Shipments must be traceable and dispatched via freight, not parcel post, with delivery address to USS HARPERS FERRY LSD 49, FPO AP 96665. The original required delivery date is August 3, 2026, and the product must be labeled with the specified manufacturer part numbers from Cardinal Health 200, LLC and Purdue Pharma LP. All documentation, including SDS and labels, must align with 29 C.F.R. 1910.1200, and supplier employees must be trained on updated hazard communication requirements. The contract is issued under solicitation SPE2DP-26-T-4384 with the NAICS code 325412 and is managed by the Department of Defense's Medical Supply Chain PHAR FSA.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
WATER FOR IRRIGATION, S
Solicitation # SPE2DP-26-T-4383
This contract specifies the procurement of sterile irrigation water, USP, in 1000 mL semi-rigid plastic containers with screw caps, optionally featuring a hanging device, intended exclusively for sterile irrigation, washing, rinsing, and dilution purposes and not for parenteral injection. The product must be distilled, nonpyrogenic, and packaged in units of issue consisting of 12 containers per package, with a non-extendable shelf life of 36 months. It is regulated by the FDA and must comply with the latest edition of Medical Marking Standard No. 1 and MIL-STD-129 for labeling and packaging, adhering to DLA’s Master List of Technical and Quality Requirements. Storage must be maintained at controlled room temperature between 20°C and 25°C, and protection from freezing and excessive heat is mandatory. The item is supplied by Baxter Healthcare Corporation under part number 2F7114 and NDC 00338-0004-04, with a unit price and total price to be determined upon award. Delivery is required FOB destination within 20 days of contract award, with zero variance allowed in quantity acceptance, and inspection and acceptance occur at the delivery point. The shipment is destined for USS ILLINOIS SSN-786 at FPO AP 96694, and compliance with DLA packaging and transportation protocols, including Fed-Std-313 and ASTM D3951 for non-hazardous materials, is required. All packaging must be palletized in accordance with RP001 and marked in full compliance with DLA standards. The solicitation, identified as SPE2DP-26-T-4383, was posted on July 30, 2026, with responses due by August 5, 2026, and the original required delivery date is August 3, 2026. The contracting official must submit a referral through EBS to confirm regulatory status, including bidder and manufacturer details, prior to award.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
POVIDONE-IODINE TOP
Solicitation # SPE2DP-26-T-4386
Povidone-Iodine Topical Solution, USP, in a 10 percent concentration, 1/2 fl oz (15 mL) bottle, is being procured in units of 50 bottles per parcel grouped under the unit of issue “PG.” The contract requires a total of two PG units, with one unit having a required delivery date of August 3, 2026, and the other by August 4, 2026, both subject to a 20-day delivery window. At the time of delivery to the first government activity, each shipment must retain at least 31 months of the full 36-month shelf life, which is non-extendable. Packaging and labeling must strictly adhere to Medical Marking Standard No. 1, superseding MIL-STD-129, and all units must be commercially packaged in sealed containers that protect against damage, with palletization conforming to DLA’s packaging requirements. The product is regulated by the FDA and classified as a critical application item, requiring compliance with all applicable DLA Master List of Technical and Quality Requirements, which take precedence over ASTM D3951 or other commercial standards. Hazardous material handling guidelines under FED-STD-313 and IP025 apply if applicable, but the item is generally expected to be commercially packaged. Shipments must be sent via traceable means, explicitly prohibiting parcel post, and delivered to designated military freight addresses in San Antonio, Texas. The manufacturer is Purdue Pharma LP with NDC 67618-0150-05, and the NSN is 6505-00-914-3593. The contracting official must submit a referral via EBS for product confirmation, including manufacturer and bidder details. Total quantity ordered is 100 bottles, with a unit price of $1.00 per PG, resulting in a total contract value of $2.00. All packaging must be marked in accordance with established government standards, and no quantity variance is permitted.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
DEXTROSE INJECTION
Solicitation # SPE2DP-26-T-4393
Dextrose Injection 5% USP, 1000 mL, is a sterile, nonpyrogenic intravenous solution supplied in single-dose plastic bags, each containing 5 grams of anhydrous dextrose USP in water for injection USP, and is labeled as latex-free. The product is intended solely for intravenous administration and is packaged in units of 12 bags per package, with a strict shelf-life requirement of 30 months that is non-extendable. Storage must be maintained between 20°C and 25°C (68°F to 77°F), protected from freezing and excessive heat, in compliance with USP controlled room temperature standards. The item is subject to the latest DLA Master List of Technical and Quality Requirements, and packaging must adhere to MIL-STD-129 and the Medical Marking Standard No. 1, with no deviation permitted from DLA specifications even if ASTM D3951 is otherwise applicable. The product is not classified as hazardous under FED-STD-313, so commercial packaging standards are secondary to DLA requirements. Two separate delivery lines are specified under contract SPE2DP-26-T-4393, each for one package of 12 units, to be delivered FOB destination within five days of shipment, with no tolerance for quantity variance. Deliveries are directed to two U.S. Navy vessels, USS Jefferson City and USS Delaware, with shipping instructions requiring traceable transport and explicitly prohibiting parcel post. The contract specifies a required delivery date of August 3, 2026, and includes government-specific identifiers, logistics codes, and procurement data tied to the NSN 6505-01-330-6252, with full technical and quality compliance governed by DLA directives that supersede all other standards.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
DOXYCYCLINE HYCLATE
Solicitation # SPE2DP-26-T-4150
The contract specifies the procurement of Doxycycline Hyclate Tablets, USP equivalent to 100 mg of doxycycline, packaged in bottles of 100 tablets each, with a total quantity of eight bottles to be delivered within 20 days after award. The item is regulated by the FDA and has a non-extendable shelf life of 36 months as a TYPE I (CODE Q) item. Packaging must comply with commercial standards as defined in the procurement document, with each unit sealed in a protective container and shipped in commercial exterior containers suitable for safe transport at the lowest cost. Medical items are subject to Medical Marking Standard No. 1, which supersedes MIL-STD-129 for all marking and labeling requirements, including barcoding and traceability, and must be followed strictly. Palletization and shipping must adhere to RP001 DLA packaging requirements, and if the product is classified as hazardous under FED-STD-313, it must be packaged per IP025; otherwise, ASTM D3951 applies but is subordinate to all DLA technical and quality requirements. The delivery is FOB destination to Fort Bragg, North Carolina, and shipments must be sent via traceable means, explicitly prohibiting the use of parcel post. The contract mandates electronic submission of payment requests through WAWF and requires compliance with numerous FAR and DFARS clauses covering equal opportunity, trafficking prohibitions, cybersecurity, hazardous materials, export controls, and small business representations. Offerors must hold valid UEI and CAGE codes and disclose any socioeconomic status, including eligibility under small business programs. All packaging and labeling must be consistent with Medical Marking Standard No. 1A dated February 4, 2013, and suppliers must ensure product integrity by storing at controlled room temperature between 20 to 25°C and protecting from light and moisture. The item’s NDC is 62135-0626-01, and the NSN is 6505-01-600-3042, with no tolerance allowed for quantity variance. The requirement to confirm bidder and manufacturer details through EBS referral to the product specialist must be fulfilled by the contracting officer prior to award.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 4 days
View Details

More opportunities from Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Same awarding agency

NAICS: 484220
New
Federal
Cold Chain Logistics and Vaccine Distribution PlanningThe contract seeks the development and validation of cold chain distribution plans specifically tailored for the rapid deployment of pandemic influenza vaccines, with a strong emphasis on packaging integrity and transport reliability under real-world conditions. The work requires designing scalable logistics frameworks that ensure vaccine stability from manufacturing through final delivery, accounting for temperature-sensitive handling, transit time constraints, and geographic variability in distribution networks. Validation protocols must rigorously test performance under stress conditions to confirm compliance with regulatory and safety standards, ensuring vaccines remain potent and viable throughout the supply chain. Deliverables will include documented distribution strategies, validated packaging systems, and tested transport methodologies suitable for immediate activation during a public health emergency. The performance location is Washington, DC, with a 20024 zip code, indicating direct alignment with federal health infrastructure. Subcontractors must respond by August 15, 2026, and the work falls under NAICS code 484220 for specialized freight trucking, reflecting the focus on secure, time-sensitive medical logistics. The contracting entity is the Department of Health and Human Services under Barda-ASPR/DAAPO, underscoring the national preparedness imperative behind this effort.
Specialized Freight (except Used Goods) Trucking, Local

POSTED

1 day ago

DEADLINE

in 15 days
View Details
NAICS: 541690
New
Federal
Pandemic Influenza Surveillance and Strain Selection SupportThe contract seeks to establish a subcontract for comprehensive global surveillance and analysis supporting the selection of pandemic influenza strains, with a focus on antigenic characterization and bioinformatics capabilities. The work involves monitoring influenza viruses worldwide to assess their antigenic properties, genetic evolution, and potential pandemic risk, enabling informed decisions for vaccine development and public health preparedness. Data collection and analysis must be conducted at a global scale, ensuring timely, accurate, and actionable insights for government health authorities. The performance location is in Washington, D.C., with a federal oversight entity under the Department of Health and Human Services, specifically Barda – ASPR/DAAPPO/Barda DCMA. The contract is categorized under NAICS code 541690, indicating it is for other scientific and technical consulting services. The opportunity was posted on July 30, 2026, with a firm deadline for responses on August 15, 2026. This subcontract aims to strengthen the nation’s capacity to anticipate and respond to emerging influenza threats by integrating real-time surveillance data with advanced analytical tools to support global influenza strain selection efforts.
Other Scientific and Technical Consulting Services

POSTED

1 day ago

DEADLINE

in 15 days
View Details
NAICS: 541611
New
Federal
Regulatory Affairs and FDA BLA Submission ManagementThe contract mandates end-to-end management of Biologics License Application submissions for influenza vaccines, with a primary focus on coordination with the FDA, timely and comprehensive responses to regulatory queries, and ongoing lifecycle management to ensure compliance and continuity. The role requires deep regulatory expertise to navigate the complexities of BLA preparation, submission, and post-submission interactions with federal authorities, ensuring all documentation and scientific data meet stringent regulatory standards. The work is scoped under a subcontract for the Department of Health and Human Services, specifically managed by Barda-ASPR, with performance concentrated in Washington, DC, at the 20024 zip code. The solicitation was posted on July 30, 2026, and responses are due by August 15, 2026, with the North American Industry Classification System code 541611 indicating specialized regulatory affairs and scientific consulting services. The position demands a high level of precision, regulatory fluency, and the ability to operate within strict federal timelines and communication protocols.
Administrative Management and General Management Consulting Services

POSTED

1 day ago

DEADLINE

in 15 days
View Details
NAICS: 541611
New
Federal
CMC Regulatory SupportThe contract requires the preparation and submission of Chemistry, Manufacturing, and Controls (CMC) sections for Biologics License Applications (BLAs) focused on influenza vaccines. This includes developing and finalizing process validation protocols, stability study designs, and comprehensive quality control documentation to meet regulatory standards for vaccine approval. The work demands precise adherence to FDA guidelines and the ability to coordinate technical data across manufacturing, testing, and regulatory teams to ensure timely and compliant submissions. The contract is classified as a subcontract under NAICS code 541611 and is issued by the Department of Health and Human Services through Barda - ASPR / DAAPPO / Barda DCMA. Performance is to be carried out in Washington, DC, with a posting date of July 30, 2026, and a hard deadline for responses on August 15, 2026. All deliverables must be structured to support the regulatory pathway for influenza vaccines, emphasizing scientific rigor, operational consistency, and compliance with current good manufacturing practices.
Administrative Management and General Management Consulting Services

POSTED

1 day ago

DEADLINE

in 15 days
View Details
NAICS: 541620
New
Federal
Analytical & Nonclinical Testing ServicesThe contract involves the execution of preclinical studies and analytical testing services for influenza vaccine candidates, focusing on critical areas such as toxicology, immunogenicity, potency, and stability assessments to support vaccine development and regulatory submission. These activities are essential for evaluating the safety, biological activity, and consistency of vaccine candidates prior to human trials, ensuring they meet quality and efficacy benchmarks. All work must be conducted in accordance with established scientific and regulatory standards to generate reliable, reproducible data that can inform further advancement of the candidates. The solicitation is designated as a subcontract under NAICS code 541620, with a response deadline of August 15, 2026, and was posted on July 30, 2026. The performance location is identified as Washington, DC, with the contracting agency listed as the Department of Health and Human Services through its Barda - ASPR/DAAPO/Barda DCMA office. While specific award details and point of contact information are not provided, the structure and timing suggest this is part of a broader effort to bolster pandemic preparedness and vaccine readiness under federal public health directives. Respondents are expected to demonstrate technical capability, compliance with nonclinical testing protocols, and experience in vaccine development support.
Environmental Consulting Services

POSTED

1 day ago

DEADLINE

in 15 days
View Details
NAICS: 541711
New
Federal
Influenza Vaccine Clinical Trial ManagementThe contract pertains to the design and management of Phase I–III clinical trials for influenza vaccines, encompassing all critical aspects from protocol development and site selection to patient recruitment and regulatory reporting to the FDA. The work requires specialized expertise in infectious disease trials, with a focus on ensuring compliance with regulatory standards and timely submission of clinical data. The performance location is in Washington, DC, with a zip code of 20024, indicating the primary operational base for trial oversight and coordination. This is a subcontract under the Department of Health and Human Services, specifically managed by Barda – ASPR / DAAPPO / Barda DCMA, with a NAICS code of 541711 indicating scientific research and development services. The opportunity was posted on July 30, 2026, with a response deadline of August 15, 2026, at 9:00 PM ET. While no set-aside type or point of contact is specified, the emphasis on end-to-end clinical trial management suggests the subcontractor must possess a proven track record in vaccine development, regulatory engagement, and multi-site trial execution under federal health security initiatives.
Research and Development in Biotechnology

POSTED

1 day ago

DEADLINE

in 15 days
View Details
NAICS: 541714
New
Federal
Presolicitation Notice - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
Solicitation # 75A50126R00001_RFP_PreSolNotice_NPIVS-2027
BARDA is seeking qualified contractors to support the ongoing Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program, requiring the provision of vaccines, antigens, and adjuvants to ensure rapid readiness for pandemic influenza or other viruses with pandemic potential. Contractors must deliver comprehensive services including manufacturing, regulatory documentation, and manufacturing readiness support, with a preference for U.S. based facilities. This includes generating and submitting all necessary analytical, nonclinical, clinical, and CMC data to the FDA, even during interpandemic periods, to enable timely regulatory decisions and sustain production capability. The program emphasizes continuous improvement of influenza vaccines with demonstrated feasibility and full lifecycle support from development through commercial-scale manufacturing. To be eligible, offerors must have a proven track record in influenza vaccine manufacturing, either by holding an active U.S. influenza vaccine license or by having successfully submitted a Biologics License Application for a seasonal or pandemic influenza vaccine. The solicitation, issued under number 75A50126R00001_RFP_PreSolNotice_NPIVS-2027, is open with a response deadline of August 15, 2026, and is administered by the Department of Health and Human Services through BARDA. All proposals must meet strict qualification criteria and align with the program’s goals of ensuring national preparedness, rapid response capacity, and regulatory compliance. Primary point of contact for inquiries is Laura Saddison at HHS.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

1 day ago

DEADLINE

in 15 days
View Details
NAICS: 541715
Federal
Animal Model Development for Phosphine & Cyanide ExposureThis contract involves the development and validation of animal models designed to accurately replicate human exposure to phosphine and cyanide. These models are intended to be used for testing medical countermeasures under the FDA Animal Rule, which provides regulatory pathways for drugs and biologics when human trials are not ethical or feasible. The work falls under the subcontract category and is associated with the Department of Health and Human Services, specifically managed by BARDA (Biomedical Advanced Research and Development Authority) and affiliated offices. The focus of the effort is to create reliable and scientifically robust animal models that can simulate the toxicological and pharmacological effects of phosphine and cyanide exposure in humans. This will facilitate the evaluation and approval of medical treatments aimed at counteracting these toxic agents in emergency or threat scenarios. The contract aligns with NAICS code 541715, which involves research and development in the physical, engineering, and life sciences sectors. The solicitation was posted in April 2026, and although specific details on location and points of contact are not provided, the contract is accessible through official government procurement platforms.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

N/A
View Details
NAICS: 541620
Federal
Expanded Biological Sample Analysis (Toxicology & Biomarkers)The contract involves the comprehensive analysis of biological samples, including blood, serum, and urine, to identify toxicological markers, conduct metabolomic profiling, and gather pharmacokinetic data. This work is aimed at assessing the safety and efficacy of medical countermeasures (MCM), supporting efforts to ensure that these interventions meet required safety standards and perform effectively in relevant scenarios. The contract falls under the NAICS code 541620, which relates to environmental consulting services, indicating specialized scientific and analytical work. Awarded by the Department of Health and Human Services through the Biomedical Advanced Research and Development Authority (BARDA), the subcontract focuses on advanced biological sample analysis as part of ongoing health protection initiatives. Although specific solicitation and contact details are not provided, the contract was posted in April 2026 and is intended to bolster toxicological and biomarker research critical to public health preparedness and response efforts. The work is conducted under the oversight of BARDA programs, underscoring its strategic importance in developing therapeutic and diagnostic solutions.
Environmental Consulting Services

POSTED

3 months ago

DEADLINE

N/A
View Details
NAICS: 541380
Federal
In Vivo Imaging and Data Acquisition (Preclinical)This contract involves conducting in vivo preclinical imaging using modalities such as MRI, CT, and PET to study live animal models during nonclinical investigations. The goal is to evaluate physiological responses to various chemical agents and medical countermeasures, supporting the assessment and development of these substances. The contract is issued as a subcontract under the NAICS code 541380 and is managed by the Department of Health and Human Services through its bureaus including BARDA and ASPR. The contract emphasizes data acquisition and analysis in preclinical settings, playing a critical role in advancing medical research and product development aimed at improving public health preparedness and response. The location details and point of contact information were not specified, but the contract was posted on April 22, 2026, reflecting ongoing efforts to support nonclinical study capabilities in biomedical research.
Testing Laboratories and Services

POSTED

3 months ago

DEADLINE

N/A
View Details
NAICS: 541611
Federal
Tissue Collection, Processing, and HistopathologyThis contract involves the collection, preservation, sectioning, and histological analysis of animal tissues following exposure to chemical agents and medical countermeasures (MCMs). The purpose is to support toxicology and efficacy assessments, ensuring thorough examination of tissue responses to these substances. The scope includes detailed processing and microscopic evaluation to provide critical data for understanding the biological effects and safety profiles of the tested agents. Issued by the Department of Health and Human Services under the BARDA-ASPR/DAAPO/BARDA DCMA umbrella, this subcontract falls under the NAICS code 541611, indicating professional, scientific, and technical services. The contract was posted on April 22, 2026, and although specific location details and points of contact are not provided, it is structured to facilitate specialized laboratory analysis essential for public health preparedness and response initiatives.
Administrative Management and General Management Consulting Services

POSTED

3 months ago

DEADLINE

N/A
View Details
NAICS: 541714
Federal
Nonclinical Animal Dose Escalation Studies (Schedule 1 Chemicals)This contract involves the execution of nonclinical dose escalation studies using highly hazardous chemical agents, such as phosphine and cyanide, in animal models. The primary goal is to evaluate the efficacy of medical countermeasures under the FDA’s Animal Rule, which allows for drug approval based on animal testing when human trials are not ethical or feasible. The work focuses on Schedule 1 chemicals, requiring strict adherence to safety and regulatory standards due to the high-risk nature of the substances involved. The contract is a subcontract under the Department of Health and Human Services, specifically managed by the Biomedical Advanced Research and Development Authority (BARDA) along with associated offices. It falls under the NAICS code 541714, which covers research and development in biotechnology. While specific details about the location of performance and points of contact are not provided, the contract supports the development of critical medical countermeasures aimed at protecting public health from chemical threats.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

3 months ago

DEADLINE

N/A
View Details